MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Takeda Pharmaceutical Company Ltd (NYSE:TAK)(OTCPK:TKPHF)
Organization & Developments: Takeda
Parents
Takeda Pharmaceutical Company Ltd (NYSE:TAK)(OTCPK:TKPHF)
Children
*Largest pharmaceutical company in Japan and one of the global leaders of the industry
*Takeda Products Ireland Ltd
2011: Amylin & Takeda Halt Obesity Drug Development (2011)
2011: Sage Starts Takeda, CHDI Work on Neurological Disorders (2011)
2016: Gates Foundation Awards $38 Million for Polio Vaccine Program
2016: Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
2016: Takeda Launches Wearable Digital Technology Pilot Program
2017: This is the first time that a pharmaceutical company and a clinical research organization (CRO) have come together to create such a comprehensive business and operational strategy
2019: Bellicum: Still Discounted After MD Anderson Deal_seekingalpha.com
2019: Global Fund Receives $9 Million From Takeda Pharmaceutical
2019: Takeda And HemoShear Therapeutics: The NASH Collaboration_seekingalpha.com
2019: What does $62B buy you these days? A lot, says Takeda execs as the pharma player promises a blockbuster R&D future – Endpoints News
2020: Arrowhead Is A Buy On Takeda Deal And Massive Pipeline
2020: COVID-19 close-up: Takeda's Morabito on the science behind plasma-based treatments
2020: How Asia’s largest pharma is leveraging its values to navigate the COVID-19 crisis
2020: Takeda teams up with Twist Bioscience to boost biologics R&D
2022: After 'watershed' approval, Takeda nears dengue vaccine launch and gears up for more green lights
2022: It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue
2022: Takeda Pharmaceutical Company Limited 2022 Q2 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Takeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration Looms_ seekingalpha.com
2022: Takeda: Momentum Building Around Core Offerings, Rate Buy_ seekingalpha.com
2022: Takeda's Takeout Of Nimbus And The 3 Amigos In The TYK2 Market - A Story With A Happy Ending?_ seekingalpha.com
2024: Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation
2024: Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
2024: Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors_seekingalpha.com
2024: Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
2024: Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline_ seekingalpha.com
Takeda Digital Ventures
Jumps
*Key People: Takeda
Finance & Acquisition: Takeda